Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Health-Related Quality of Life as a Prognostic Measure of Clinical Outcomes in Renal Cell Carcinoma: A Review of the CheckMate 025 Trial

Health-Related Quality of Life as a Prognostic Measure of Clinical Outcomes in Renal Cell... The phase III, randomized, open-label CheckMate 025 study showed an overall survival benefit in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus. Here, we review the health-related quality of life (HRQoL) results of this trial, in which nivolumab was associated with significant improvements in HRQoL, with more patients having a clinically meaningful HRQoL improvement and a shorter time to onset of improvement compared with everolimus. Further exploratory analysis suggests a positive correlation between baseline HRQoL scores and overall survival. These results support the use of HRQoL as a valuable measure of patient perspective that could translate into better clinical outcomes and should be taken into account during treatment selection. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Health-Related Quality of Life as a Prognostic Measure of Clinical Outcomes in Renal Cell Carcinoma: A Review of the CheckMate 025 Trial

Grimm, Marc-Oliver; Grünwald, Viktor
Oncology and Therapy , Volume 5 (1) – Mar 23, 2017
Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/health-related-quality-of-life-as-a-prognostic-measure-of-clinical-4oTUkMzsii
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-017-0042-6
Publisher site
See Article on Publisher Site

Abstract

The phase III, randomized, open-label CheckMate 025 study showed an overall survival benefit in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus. Here, we review the health-related quality of life (HRQoL) results of this trial, in which nivolumab was associated with significant improvements in HRQoL, with more patients having a clinically meaningful HRQoL improvement and a shorter time to onset of improvement compared with everolimus. Further exploratory analysis suggests a positive correlation between baseline HRQoL scores and overall survival. These results support the use of HRQoL as a valuable measure of patient perspective that could translate into better clinical outcomes and should be taken into account during treatment selection.

Journal

Oncology and Therapy – Springer Journals

Published: Mar 23, 2017

References

  • Pazopanib versus sunitinib in metastatic renal-cell carcinoma
    Motzer, RJ; Hutson, TE; Cella, D; Reeves, J; Hawkins, R; Guo, J; Nathan, P; Staehler, M; Souza, P; Merchan, JR; Boleti, E; Fife, K; Jin, J; Jones, R; Uemura, H; Giorgi, U; Harmenberg, U; Wang, J; Sternberg, CN; Deen, K; McCann, L; Hackshaw, MD; Crescenzo, R; Pandite, LN; Choueiri, TK
  • Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
    Escudier, B; Porta, C; Bono, P; Powles, T; Eisen, T; Sternberg, CN; Gschwend, JE; Giorgi, U; Parikh, O; Hawkins, R; Sevin, E; Négrier, S; Khan, S; Diaz, J; Redhu, S; Mehmud, F; Cella, D
  • Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
    Cella, D; Grünwald, V; Nathan, P; Doan, J; Dastani, H; Taylor, F; Bennett, B; DeRosa, M; Berry, S; Broglio, K; Berghorn, E; Motzer, RJ
  • Nivolumab versus everolimus in advanced renal-cell carcinoma
    Motzer, RJ; Escudier, B; McDermott, DF; George, S; Hammers, HJ; Srinivas, S; Tykodi, SS; Sosman, JA; Procopio, G; Plimack, ER; Castellano, D; Choueiri, TK; Gurney, H; Donskov, F; Bono, P; Wagstaff, J; Gauler, TC; Ueda, T; Tomita, Y; Schutz, FA; Kollmannsberger, C; Larkin, J; Ravaud, A; Simon, JS; Xu, LA; Waxman, IM; Sharma, P